Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 11.3% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price rose 11.3% during mid-day trading on Friday . The stock traded as high as $0.70 and last traded at $0.63. Approximately 151,239,068 shares changed hands during trading, an increase of 431% from the average daily volume of 28,475,689 shares. The stock had previously closed at $0.57.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Sunday, December 15th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Up 7.8 %

The stock’s 50-day simple moving average is $0.19 and its 200-day simple moving average is $0.52. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $114.85 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.